



**IMMUNOGENICITY OF FLUAD® (MF-59 ADJUVANTED TIV) VACCINE AGAINST ANTIGENICALLY DRIFTED INFLUENZA STRAINS IN OLDER ADULTS**


Maureen Tham on behalf of James A. Mansi<sup>1</sup>  
June 2018

<sup>1</sup>Seqirus Inc., Montreal, QC, Canada


**AIM:** Evaluate the immunogenicity of Fludac or standard TIV against heterologous strains in older adults

**4 RCTs: GMT Ratios - Heterologous Strains (FAS)**

- Antibody responses by haemagglutination inhibition (HI) were examined against antigenically drifted strains using sera from subjects immunised with either Fludac (aTIV) or a non-adjuvanted TIV comparator in 4 clinical trials in older adults 65 years and over.




**4 RCTs: Seroconversion Rate Differences - Heterologous Strains**



**Fludac Expands Serologic Coverage of 14/15 NH H3N2 Mismatch – Microneutralisation assay**

- To specifically examine the heterologous antibody response against the antigenically drifted H3N2 strain during the 2014-2015 season, sera from two 2013/14 NH seasonal licensure Phase II trials were used



Seroconversion: Fourfold or greater increase in antibody titres over pre-vaccination titres



**Conclusions**

- In clinical trials and post licensure studies in older adults, Fludac demonstrated increased breadth of antibody responses in comparison to non-adjuvanted comparators.
- A closer look at these data suggests that Fludac generated a higher percentage of significant titre increase against both matched and mismatched strains.
- These data further emphasise the potential benefit of Fludac in older adults, particularly during influenza seasons where drift occurs.

Please refer to Product Information for Fludac before prescribing

